Presented by: Ronan Rooney, IBM Research, Director of Care Programs
Learn more: http://www.ibm.com/software/products/en/category/health-social-programs
This is the first report on Telehealth in India, and was authored in 2011 by Rajendra Pratap Gupta for Telemedicine Society of India , when he chaired the Organising Committee of the International Telemedicine Congress 2011 at Mumbai
This report gives a detailed overview of where India stands and what is the scope in future
This is the magazine of the Ministry of Health & Family Welfare , Government of India . It will be a quarterly magazine dealing with health issues relevant to the public
This presentation is by Mr.Rajendra P. Gupta at the Putting Patients First Conference on 20th Oct,10. Topic " Role of patients in the healthcare system". HELP is the world's largest the worlds largest free patient education library - www.healthlibrary.com
Presented by: Ronan Rooney, IBM Research, Director of Care Programs
Learn more: http://www.ibm.com/software/products/en/category/health-social-programs
This is the first report on Telehealth in India, and was authored in 2011 by Rajendra Pratap Gupta for Telemedicine Society of India , when he chaired the Organising Committee of the International Telemedicine Congress 2011 at Mumbai
This report gives a detailed overview of where India stands and what is the scope in future
This is the magazine of the Ministry of Health & Family Welfare , Government of India . It will be a quarterly magazine dealing with health issues relevant to the public
This presentation is by Mr.Rajendra P. Gupta at the Putting Patients First Conference on 20th Oct,10. Topic " Role of patients in the healthcare system". HELP is the world's largest the worlds largest free patient education library - www.healthlibrary.com
This was a presentation made as an 'Opening Keynote address' at the HIMSS India Dialogue'13 at New Delhi on the topic' State of Healthcare IT in India - Next five years'
Opening keynote on Healthcare Reforms in India presented at the National Conference on Safe and Sustainable Hospitals on 13th September , 2014 at Ramaiah Medical College , Bangalore
Why KAM Fails in Pharma, Job Satisfaction Survey Results. Pharma Rural Marketing. Coaching in Pharma. 9 Simple Steps to Better Team Management. Basics of Pharmacology for Medical Reps and more
JourneyLabs improves participant outcomes in high-stakes relationships such as in healthcare, workplace, education, and professional services markets. Our proprietary cloud and mobile platform optimizes enhanced information collection to enable responsive action, as well as long-term relationship analytics. JourneyLabs is based in Winter Spring, Florida and Pune, India. For more information, please visit www.journeylabs.io.
Our Journey Management Platform
The JourneyLabs™ Journey Management Platform operationalizes long term interactions and improves participant outcomes in high-stakes relationships.
Organizations can easily build and deliver highly personalized digital journeys for each participant that can be delivered anywhere, anytime, while retaining a longitudinal record and key data for analytics.
Buddy is a digital tool to support therapy services. Clients use text messaging to keep a daily diary of what they are doing and how they are feeling, helping to spot and reinforce positive behaviours. Find out more at www.buddyapp.co.uk
As a member of the National Education Policy Committee, Ministry of Human Resources, Government of India. I traveled to remote villages, saw the reality on the ground, discussed the issues with students for whom we were drafting the policy, met teachers and parents. You can see how such practical work helped shaped the National Education Policy. And I am fortunate that all these inputs have made their way in the NEP. Worth the efforts.
This was a presentation made as an 'Opening Keynote address' at the HIMSS India Dialogue'13 at New Delhi on the topic' State of Healthcare IT in India - Next five years'
Opening keynote on Healthcare Reforms in India presented at the National Conference on Safe and Sustainable Hospitals on 13th September , 2014 at Ramaiah Medical College , Bangalore
Why KAM Fails in Pharma, Job Satisfaction Survey Results. Pharma Rural Marketing. Coaching in Pharma. 9 Simple Steps to Better Team Management. Basics of Pharmacology for Medical Reps and more
JourneyLabs improves participant outcomes in high-stakes relationships such as in healthcare, workplace, education, and professional services markets. Our proprietary cloud and mobile platform optimizes enhanced information collection to enable responsive action, as well as long-term relationship analytics. JourneyLabs is based in Winter Spring, Florida and Pune, India. For more information, please visit www.journeylabs.io.
Our Journey Management Platform
The JourneyLabs™ Journey Management Platform operationalizes long term interactions and improves participant outcomes in high-stakes relationships.
Organizations can easily build and deliver highly personalized digital journeys for each participant that can be delivered anywhere, anytime, while retaining a longitudinal record and key data for analytics.
Buddy is a digital tool to support therapy services. Clients use text messaging to keep a daily diary of what they are doing and how they are feeling, helping to spot and reinforce positive behaviours. Find out more at www.buddyapp.co.uk
As a member of the National Education Policy Committee, Ministry of Human Resources, Government of India. I traveled to remote villages, saw the reality on the ground, discussed the issues with students for whom we were drafting the policy, met teachers and parents. You can see how such practical work helped shaped the National Education Policy. And I am fortunate that all these inputs have made their way in the NEP. Worth the efforts.
As a member of the National Education Policy Committee, Ministry of Human Resources, Government of India. I traveled to remote villages, saw the reality on the ground, discussed the issues with students for whom we were drafting the policy, met teachers and parents. You can see how such practical work helped shaped the National Education Policy. And I am fortunate that all these inputs have made their way in the NEP. Worth the efforts.
This was the largest ever survey on healthcare done by a private group. Disease Management Association of India ( www.dmai.org.in) led this study of 60,000 people across 12 states in India on the state of healthcare. This helped the policy makers a lot on putting forth the facts as per the primary study
Without 'Digital Health for all', we can never achieve 'Healthcare for all - Universal Healthcare'. Prof. Rajendra Pratap Gupta
This article explores in depth about the current state of the digital health industry, and what the industry and the Government needs to do to transform it. We are at an inflexion point and we cannot lose any more time. We need to work together to make 'Digital Health for All' and 'Universal Digital Health' a reality to ensure 'Healthcare for all'. Without 'Digital Health for all', we can never achieve 'Healthcare for all - Universal Healthcare'. Prof. Rajendra Pratap Gupta
This global index provides the first-ever snapshot of digital health ecosystems throughout the world and lays the foundation for better informed and more coordinated investments in digital health
The first live guidelines from the World Health Organization
(WHO) on Digital Health. I was a member of the guidelines development group for this report
Report on the 5th Government Industry Dialogue on Digital Health, Medical Devices & Interoperability . This report is based on the deliberations of the the dialogue held between all stake-holders on 19th April hosted by the Disease Management Association of India , PCHA , Continua in partnership with Ministry of Health & Family Welfare , Department of Pharma , NHSRC, TIFAC , Government of India
State of Healthcare IT in India is the first report from HIMSS India.. This will be quite helpful for policy makers and the industry alike . We look forward to bringing out more reports in the times ahead
The small and medium hospitals always bear the brunt of wrong solutions being developed and deployed . This checklist was developed by HIMSS to help small and medium Indian hospitals to have the right RFP for developing their software solutions . This will be a great help for hospitals who cannot afford high end solutions but still need to develop one like them
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.